The Japanese Global Health Innovative Technology Fund (GHIT) has produced two short videos and shot on location in Uganda, South East Asia and Burkina Faso, the latter being where the SEmalvac project, funded by GHIT, is ongoing.  The main objective is to assess the safety and immunogenicity of the recombinant Escherichia coli BK-SE36 malaria vaccine candidate in healthy malaria exposed African children.  GHIT support also aims to improve maternal health and child survival through innovative means and strategies.  Health improvement will secure well being and productivity.  These two movies stress the need to maintain a sustainable partnership.

The Global Health Innovative Technology Fund (GHIT) annual partners meeting was held on 7 June at Roppongi, Japan.

Prof Toshi Horii and Dr Sodiomon Sirima gave presentations in session 1 "innovation and impact".

The European & Developing Countries Clinical Trials' Partnership (EDCTP) invites nominations to the following awards: Scientific Leadership Award, Outstanding Female Scientist Award and Outstanding Research Team Award.

Congratulations to Thorsten Kohaut, whose well deserved promotion to Chief Financial Officer came into effect on 1 May 2016.

EVI extends a warm welcome to two new team members.  Hilde Depraetere joined EVI on 1 July as Senior Project Manager, and yesterday 6 July Leah Williams commenced duties as Programme Manager Assistant.

The second EDUFLUVAC workshop on experimental animal models for universal influenza vaccines took place on 23-24 June 2016 at the Biomedical Primate Research Centre, Rijswijk, The Netherlands.  The workshop was organised by EDUFLUVAC, EU - Framework programme 7 funded project with the financial support of Sanofi Pasteur and Viroclinics.

A warm welcome is extended to EVI's new Project Manager, Soazic Gardais, who commenced duties on 27 June 2016.

The following products are now available on the The National Institute for Biological Standards and Control (NIBSC) website:

Influenza Virus Infectious NIBRG-306 ( Influenza Reagent )

23-06-2016 01:00 AM BST

As of 15 June 2016 EVI is domiciled at:

European Vaccine Initiative UniversitätsKlinikum Heidelberg Vossstrasse 2, Geb. 4040 69115 Heidelberg, Germany

European public and private organisations are collaborating in VAC2VAC, a new project funded by the Innovative Medicines Initiative (IMI2) to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods.